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Summary
Objective: To investigate the working mechanism of glucosamine (GlcN) by studying the effect of different GlcN derivatives on bovine chon-
drocytes in alginate beads under anabolic and catabolic culture conditions.
Methods: Bovine chondrocytes seeded in alginate beads were treated with different concentrations of glucosamineesulfate (GlcN-S), gluco-
samineehydrochloride (GlcN-HCl) or N-acetyleglucosamine (GlcN-Ac). Culture conditions were anabolic, 3 day pre-culture followed by 14
days’ treatment; catabolic, extracellular matrix (ECM) breakdown induced by 10 ng/ml interleukin-1b (IL-1b); or a situation with balance
between ECM breakdown and synthesis, 24 days’ pre-culture followed by 14 days’ treatment. The outcome measurements were total glyco-
saminoglycan (GAG) and DNA content per bead.
Results: In the situation with balance between ECM breakdown and synthesis, GlcN-Ac had a small stimulatory effect on total GAG content.
GlcN-S and GlcN-HCl had no effect. Under anabolic condition 5 mM GlcN-S and GlcN-HCl signiﬁcantly reduced total GAG content. GlcN-Ac
did not show this effect. IL-1b induced catabolic effects were prevented by adding 5 mM GlcN-HCl. Interference of GlcN with glucose (Gluc)
was demonstrated by adding extra Gluc to the medium in the anabolic culture conditions. Increasing extracellular Gluc concentrations dimin-
ished the effect of GlcN.
Conclusion: GlcN-S and GlcN-HCl, but not GlcN-Ac, reduce anabolic and catabolic processes. For anabolic processes this was demonstrated
by decreased ECM synthesis, for catabolic processes by protection against IL-1b mediated ECM breakdown. This might be due to interfer-
ence of GlcN with Gluc utilization. We suggest that the claimed structure modifying effects of GlcN are more likely based on protection against
ECM degradation than new ECM production.
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SocietyIntroduction
Nutraceuticals, in particular glucosamine (GlcN), are in-
creasingly used as a treatment option for osteoarthritis
(OA). Over the last decades an ever increasing number of
patients have started using GlcN, with or without a prescrip-
tion of their physician. Although the effectiveness of GlcN
has been debated in a recent article reporting a large NIH
trial, subgroup analysis indicated that there might be an ef-
fect in people with mild to severe OA1. Other clinical studies
suggested that GlcN probably has structure modifying ef-
fects in patients with knee OA2,3. The underlying effects
of GlcN on cartilage, responsible for these clinical out-
comes, are still not clear. Conﬂicting results on this topic
in in vitro experiments are reported in the literature. It has
been proposed that addition of GlcN to chondrocyte cell cul-
tures leads to more glycosaminoglycan (GAG) production,
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Received 5 September 2006; revision accepted 15 April 2007.126since GlcN is the basic building block of GAG molecules.
Some studies showed results in favor of this hypothesis4e8.
But, other studies could not conﬁrm this effect9,10. And fur-
thermore there are studies that observed negative effects
on GAG production after GlcN addition11e16. Apart from
inﬂuencing matrix synthesis, several studies have shown
that GlcN is also able to interfere with enzymatic matrix deg-
radation5,10,12,17e21. These conﬂicting results can have var-
ious causes. It is debated whether glucosamineesulfate
(GlcN-S), glucosamineehydrochloride (GlcN-HCl) and N-
acetyleglucosamine (GlcN-Ac) have similar effects on carti-
lage or not. Differences in the results can also be explained
by the variety of culture models (e.g., monolayer vs pellet
culture) and the variation in culture durations that have
been used. Most studies were cultured for a relatively short
period, so the chondrocytes were not yet surrounded by an
extracellular matrix (ECM) and hence the effect of GlcN
is tested in an anabolic state. To test the effect of GlcN
in a catabolic situation ECM degrading substances, e.g.,
interleukin-1b (IL-1b), lipopolysaccharide or retinoic acid,
are used by several investigators to mimic an OA like
environment5,7,11e13,15,16,18e25.
The aim of this series of experiments was to determine the
effects of different GlcN derivatives on chondrocyte matrix
production in a three-dimensional (3D) culture model:7
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to be formed, (2) in a situation of balance between GAG syn-
thesis and degradation where ECM already has been
formed, (3) under catabolic conditions, through the addition
of IL-1b. For all conditions we cultured chondrocytes in algi-
nate beads since this is a widely accepted model to test
chondrocyte behavior in a 3D environment26.
Since some authors have postulated that competition be-
tween GlcN and glucose (Gluc) might be the basis for the
mechanism of action of GlcN, we also tested the effect of
increasing Gluc levels in the culture medium9,18,27,28.
Materials and methods
ALGINATE CULTURES
Cartilage slices were dissected from the metacarpo-
phalangeal joint of 6e12 months old calves under asepti-
cally conditions and washed with physiological saline.
Slices were incubated with pronase E in physiological sa-
line (2 mg/ml; Sigma, St Louis, MO) for 1 h at 37C followed
by overnight incubation with collagenase B (1.5 mg/ml;
Roche diagnostics Mannheim, Germany) in medium with
10% fetal calf serum (FCS). Undigested parts were re-
moved using a 100 mm ﬁlter and isolated chondrocytes
were washed with physiological saline. Cell viability was
tested using the trypan blue exclusion test. Cells were sus-
pended at a density of 4 106 cells/ml in sterile saline con-
taining 1.2% low-viscosity alginate (Keltone LV, Kelco), and
slowly, in a dropwise fashion, pressed through a 23-gage
needle into a 102 mM CaCl2 solution. After instantaneous
gelation, the beads were allowed to polymerize further for
a period of 10 min in the CaCl2 solution. Then, beads
were washed with saline and cultured with 10 beads per
well in 24-well plates with 500 ml DMEM (Gibco, Grand Is-
land, NY) low Gluc (1000 mg/l, l¼ 5.55 mM) supplemented
with 10% FCS, 50 mg/ml gentamicin, 1.5 mg/ml fungizone
and 25 mg/ml freshly added L-ascorbic acid-2-phosphate.
After a 3 day recovery period (pre-culture) the experiment
was started. In all experiments medium was changed three
times a week.
EXPERIMENTAL DESIGN
Experiment 1: GlcN effects on chondrocytes
already surrounded by ECM
The purpose of this experiment was to test the effect of
Gluc (Sigma, St Louis, MO), GlcN-HCl (Sigma, St Louis,
MO), GlcN-S (Sigma, St Louis, MO) and GlcN-Ac (Sigma,
St Louis, MO) on bovine chondrocytes in a situation of bal-
ance between GAG synthesis and degradation, i.e., in the
presence of a preexisting ECM. Therefore experiment 1
started with a prolonged pre-culture period of 21 days
(days 3e24) without any experimental interference. Then,
treatment started by adding Gluc 5 mM or GlcN derivatives
(0.1, 0.5 and 5 mM) to the culture medium for 14 days (days
24e38). This experiment was repeated three times (N¼ 3).
For each experimental condition, three samples of three
beads each were harvested at day 38 and biochemical
analysis was performed as described later.
An earlier study showed that the typical chondrocytic ap-
pearance and spherical shape of bovine chondrocytes cul-
tured in alginate beads are retained for at least 5 weeks26.
We therefore decided that a 38 day culture period was
within a safe margin for investigating real chondrocyte
behavior.Experiment 2a: GlcN effects in anabolic conditions
In order to test the effect of GlcN on bovine chondrocytes
under mainly anabolic conditions, i.e., where the ECM still
has to be formed, the alginate beads were treated for 14
days as in experiment 1 but with treatment starting on day
3 (days 3e17). This experiment was performed three times
(N¼ 3). Three samples of three beads per condition were
harvested at day 17 for biochemical analysis.
Experiment 2b: GlcN effects in anabolic
conditions: a time course
Here, the effect of GlcN on the developing ECM during
the ﬁrst 17 days of culture was studied in detail in time. Cul-
ture was performed similar to experiment 2a, except that
beads were harvested at days 3, 6, 10 and 17. As a mea-
sure for ECM development, we investigated total amount
of GAG per bead. This experiment was performed twice
for the 5 mM conditions only (N¼ 2).
Experiment 3: GlcN effects in catabolic conditions
In this experiment IL-1b addition is used as a model to
study the effects of GlcN under catabolic conditions. On
day 8, the 10% FCS in the medium was washed out in three
washing steps prior to culturing beads in low Gluc DMEM
supplemented with 2% FCS with or without 10 ng/ml
IL-1b for 48 h. On day 10, the IL-1b was washed out
using the same washing protocol. From day 10 to 17 the
alginate beads were again cultured in medium with 10%
FCS.
In this series of experiments four experimental conditions
were created:
(1) control culture for 17 days in low Gluc medium;
(2) IL-1b treatment for 48 h, starting on day 8, as de-
scribed above;
(3) as in condition 1, but with 5 mM GlcN-HCl added on
day 6 for 96 h;
(4) as in condition 2, but with 5 mM GlcN-HCl added on
day 6 for 96 h.
This experiment was repeated three times (N¼ 3). Three
samples of three beads each were harvested for each con-
dition at days 6, 8, 10, 13 and 17 for biochemical analysis.
Experiment 4: GlcN effects with increasing
medium Gluc concentration
The purpose of experiment 4 was to investigate the al-
leged competition between GlcN and Gluc. This was tested
in the situation without a preexisting ECM, since we ex-
pected that chondrocytes in this anabolic situation are
highly in need for both Gluc and GlcN, so competition
was expected to be the highest in this situation. As in exper-
iment 2a, experimental treatment started immediately on
day 3 for 14 days, with 5 mM GlcN-HCl and GlcN-Ac. An
additional 5, 10 or 20 mM Gluc was added to the basal
Gluc level of 5.55 mM in the culture medium, resulting in
ﬁnal concentrations of 5, 10, 15 and 25 mM Gluc. This
experiment was repeated twice (N¼ 2). On day 17, three
samples of three beads each were harvested and the
amount of GAG measured.
In Fig. 1, the time course of addition of GlcN and IL-1b in
the four experiments with respect to the ECM status, based
on the data of the control conditions in experiments 1 and
2b, is displayed.
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Beads were dissolved by adding 100 ml of 55 mM sodium
citrate in 150 mM NaCl per bead for 15 min at 4C. After ad-
dition of an equal volume of papain (Sigma, St Louis, MO),
resulting in a concentration of 125 mg/ml, the beads were in-
cubated overnight at 60C. After the overnight incubation
the samples were vortexed and incubated for another 2 h
at 60C.
To evaluate the total number of chondrocytes present in
the beads at the given time points, the amount of DNA
was measured. The amount of DNA was quantiﬁed in
a spectroﬂuorometer (PerkineElmer LS-2B) by its 365 nm/
440 nm ratio using Hoechst 33258 dye with calf thymus
DNA (Sigma, St Louis, MO) as a standard29.
The results in our previous study indicated that addition of
GlcN might lead to inhibition of matrix synthesis as well as
degradation30. For this study we have chosen to quantify
the total amount of GAG present in the beads using the
DMB assay to provide us with the resultant of GAG produc-
tion and degradation.
The amount of GAG was quantiﬁed using a modiﬁed
Farndale assay in microtiter plates, with the pH of the dime-
thylmethylene blue solution set to 1.5 to prevent interfer-
ence with alginate31,32. Brieﬂy, the metachromatic reaction
of GAG with dimethylmethylene blue is monitored by its
A540/A595 ratio in a spectrophotometer. Chondroitin sul-
phate (CS) C (Shark; Sigma, St Louis, MO) was used as
a standard. If necessary, samples were diluted to be sure
to measure within the linear range of the assay.
DATA ANALYSIS
In the experiments, data from the individual experimen-
tal conditions consisted of the analysis of three samples
of three beads each. The means of these data of each
experiment were used to calculate and display mean
and standard deviations for the amount of DNA and
GAG (N¼ 3 for experiments 1, 2a and 3; N¼ 2 for exper-
iments 2b and 4). For statistical analysis, a KruskaleWallis
test with post hoc ManneWhitney U test was performed
using the data of all individual samples using SPSS 11.0.1
(SPSS Inc., Chicago, IL). Thus statistics are based on nine
samples (N¼ 3 3 for experiments 1, 2a and 3) and
six samples (N¼ 2 3 for experiments 2b and 4). A
P-value< 0.05 was considered to indicate statistically signif-
icant differences.
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Fig. 1. ECM status (based on the data of the control conditions from
experiments 1 and 2b) and time course of experimental conditions.
e GlcN addition in experiment 1. e GlcN addition in ex-
periments 2 and 4. e GlcN addition in experiment 3. e
IL-1b treatment in experiment 3.Results
EXPERIMENT 1: GLcN EFFECTS ON CHONDROCYTES
ALREADY SURROUNDED BY ECM
When GlcN is added for 14 days to chondrocytes that had
ﬁrst been allowed to form an ECM (addition from day 24 to
38 of culture) no statistically signiﬁcant effect on the amount
ofGAGper beadwas found compared to the control condition,
except for 5 mM GlcN-Ac [Fig. 2(A)]. Addition of GlcN-Ac
showed a dose-dependent trend, with a 40% increase in the
amount of GAG per bead for the highest concentration,
5 mM GlcN-Ac (P¼ 0.003). Considering the amount of DNA
perbead [Fig.2(B)], onlyadditionof5 mMGlcN-S led toasmall
but statistically signiﬁcant increase compared to the control
condition (0.81 0.03 mg vs 0.74 0.07 mg; P< 0.001).
EXPERIMENT 2A: GLcN EFFECTS IN ANABOLIC CONDITIONS
The amount of GAG per bead was signiﬁcantly reduced
with 0.5 mM GlcN-HCl (9.46 1.7 mg vs 10.07 2.3 mg;
P¼ 0.04), 5 mM GlcN-HCl (4.44 1.78 mg; P¼ 0.001),
0.5 mM GlcN-S (6.55 0.18 mg; P¼ 0.024) and 5 mM
GlcN-S (2.76 0.32 mg; P< 0.001) compared to the con-
trol. The effect of the different GlcN derivatives on the
GAG content per bead is displayed in Fig. 3(A). The result
of the different GlcN derivatives on the amount of DNA per
bead is shown in Fig. 3(B). A dose-dependent relation was
found for GlcN-HCl and GlcN-S, i.e., with increasing GlcN
concentration, the total amount of DNA per bead decreases.
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Fig. 2. Total amount of GAG per bead (expressed as mg CS; panel
A) and total amount of DNA per bead (panel B) on day 38 after stim-
ulation with GlcN. Three concentrations of three different forms of
GlcN were added during the last 14 days of culture. An ECM was
preformed during the ﬁrst 24 days and the effects of GlcN are
thus tested in a situation where a balance between synthesis and
degradation exists. * indicates a statistically signiﬁcant difference
(P< 0.05), compared to the nonsupplemented control.
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tent per bead was statistically signiﬁcant.
Addition of 5 mMGluc to chondrocytes in vitro fromday 3 to
17 did not signiﬁcantly inﬂuence theGAG or DNA content per
bead, nor did any of the tested concentrations of GlcN-Ac.
EXPERIMENT 2B: GLcN EFFECTS IN ANABOLIC CONDITIONS:
A TIME COURSE
The decreased amount of DNA and GAG per bead upon
addition of GlcN-S and GlcN-HCl during the anabolic phase
of culture as observed in experiment 2a was further evalu-
ated in a time course study. For this experiment we used
a limited number of conditions (5 mM GlcN-HCl, 5 mM
Gluc, and control), but the culture scheme was similar to ex-
periment 2a. The amount of GAG and DNA per bead in-
creases in time in the control condition (Fig. 4). Addition
of GlcN-HCl from the start of the experiment inhibited this
increase. The reduction in the amount of GAG per bead
compared to the control was already statistically signiﬁcant
at day 6 (1.73 0.46 mg vs 3.01 0.76 mg; P< 0.001). Ad-
dition of 5 mM Gluc led to an even higher GAG content per
bead when compared to the control, but only statistically
signiﬁcant at day 10 (7.92 1.92 mg vs 6.23 1.57 mg;
P¼ 0.008). An effect on the amount of DNA per bead
became only signiﬁcant at day 17. GlcN-HCl reduced
(0.41 0.12 mg vs 0.57 0.07 mg; P¼ 0.004) and 5 mM
Gluc increased the amount of DNA per bead when com-
pared to the control condition (0.68 0.10 mg vs 0.57
0.07 mg; P¼ 0.016).
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Fig. 3. Total GAG content (panel A) and total DNA content (panel B)
per bead upon GlcN treatment on day 17. Chondrocytes were stim-
ulated in the absence of an ECM and the GlcN effects are thus
tested in an anabolic situation. Three different forms of GlcN, three
concentrations each, were added during the last 14 days of culture.
* indicates a statistically signiﬁcant difference (P< 0.05), compared
to the nonsupplemented control.EXPERIMENT 3: GLcN EFFECTS IN CATABOLIC CONDITIONS
Addition of 10 ng/ml IL-1b from day 8 till day 10 de-
creases the total amount of GAG per bead, reaching the
maximal effect between day 10 and day 13 (Fig. 5). On
day 13, the total amount of GAG per bead signiﬁcantly dif-
fers from the control (7.59 1.28 mg vs 10.49 1.33 mg;
P< 0.001). Between day 13 and day 17 the amount of
GAG per bead in the IL-1b treatment group recovers by in-
creasing at a faster rate than the control group.
As expected, based on our earlier results, the addition of
5 mM GlcN-HCl on day 6 for 96 h led to a reduced total
amount of GAG per bead when compared to the nonsupple-
mented control, reaching statistical signiﬁcance from day 10
onwards. Addition of 10 ng/ml IL-1b to the alginate beads
pre-treated with 5 mM GlcN-HCl did not lead to a statistically
signiﬁcant further reduction in the total amount of GAG per
bead (Fig. 5). Thus, pre-treatment with 5 mM GlcN-HCl
seems to protect chondrocytes against the IL-1b triggered,
destructive effects observed without GlcN treatment.
EXPERIMENT 4: GLcN EFFECTS WITH INCREASING MEDIUM
GLuC CONCENTRATION
Here, we investigated the alleged competition between
Gluc and GlcN. Overall, the GAG content per bead in-
creased with increasing concentrations of extracellular
Gluc (Fig. 6). The GlcN-HCl condition revealed an increase
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Fig. 4. Changes in GAG per bead (panel A) and DNA per bead
(panel B) upon GlcN treatment during 17 days of culture. Cultures
were treated with 5 mM Gluc and 5 mM GlcN-HCl during the last 14
days. Beads were harvested on days 3, 6, 10 and 17. In the ab-
sence of ECM, the GlcN effects are tested in an anabolic situation.
* indicates a statistically signiﬁcant difference (P< 0.05), compared
to the nonsupplemented control.
1271Osteoarthritis and Cartilage Vol. 15, No. 11in GAG per bead that dose-dependently correlates with the
Gluc concentration. This Gluc dependent increase in GAG
content was far less pronounced in the control and the
GlcN-Ac condition (Fig. 6). In the presence of 15 or
25 mM Gluc, GlcN-HCl no longer signiﬁcantly reduced the
GAG content per bead compared to the control condition
at 5 mM Gluc.
Discussion
Addition of GlcN-HCl or GlcN-S did not have a signiﬁcant
effect on total GAG content per bead when added in vitro
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concentration.to ECM surrounded chondrocytes (experiment 1). In an an-
abolic culture environment, addition of 5 mM GlcN-HCl and
GlcN-S even reduced the GAG content per bead com-
pared to the control condition. In contrast, GlcN-Ac did
not show this effect. It even appeared to have a small stim-
ulatory effect on GAG content in ECM surrounded chon-
drocytes (experiments 1 and 2). The apparently inhibitive
effect of GlcN-HCl and GlcN-S on GAG content could be
diminished by increasing the extracellular Gluc concentra-
tion (experiment 4), indicating an interference with Gluc
metabolism. On the other hand, this interference also
seems to prevent the catabolic effects induced by 10 ng/ml
IL-1b (experiment 3).
In an earlier study with GlcN added to human OA explant
cultures, we found down-regulation of marker genes for an-
abolic (collagen II and aggrecan) and catabolic (a disinte-
grin and metalloproteinase with a thrombospondin type
motif (ADAMTSs), and matrix metalloproteinases (MMPs))
processes30. For the MMPs we showed this by measuring
protein activity, but the effect of GlcN derivatives on GAG
content was not investigated in this earlier study. In accor-
dance with our previous study we have now shown that ad-
dition of both GlcN-S and GlcN-HCl also leads to less GAG
production, when added to isolated chondrocytes in vitro.
Furthermore we showed that treatment of chondrocytes
with GlcN leads to protection against catabolic processes
that were induced by adding IL-1b. This, again, is in agree-
ment with our previous ﬁndings on osteoarthritic explants. In
a recent study by Gouze et al., where addition of 20 mM
GlcN-HCl to rat chondrocytes led to protection against IL-
1b induced expression of genes known to be involved in
matrix degradation these results were again conﬁrmed33.
GlcN-HCl did not seem to stimulate the expression of genes
involved in matrix synthesis. In an earlier article, Gouze
et al. investigated the effect of different concentrations of
GlcN varying between 4.6 and 20.9 mM and IL-1b on pro-
teoglycan synthesis, using rat chondrocytes in alginate, in
the presence of 5.5 mM Gluc, the same medium Gluc con-
centration we used in our experiments19. They found that,
except for the lowest 4.6 mM concentration, GlcN treatment
signiﬁcantly reduced the inhibition of proteoglycan synthe-
sis by IL-1b. These results are fairly consistent with our
data from experiment 3. The main difference between our
results and those in the two mentioned studies by Gouze
et al. is that we have shown signiﬁcant effects with
a 5 mM GlcN concentration, which is far lower than the
supraphysiological dose used by Gouze and co-workers.
We found that total amount of GAG was lower when
5 mM GlcN-HCl or GlcN-S was added under anabolic cul-
ture conditions to the alginate embedded chondrocytes,
and that GlcN-Ac did not show such an effect (experiment
2). For the amount of DNA, similar results were found.
These results are a general conﬁrmation of what Terry
et al. found in their study34. They found a dose-dependent
inhibition of cell proliferation and proteoglycan synthesis
upon addition of 0.1e5 mM GlcN-HCl in their anchorage-
dependent cultures. Addition of GlcN-Ac in this culture sys-
tem did not lead to inhibition. For the anchorage-independent
culture system, i.e., alginate beads, the inhibitory effects of
GlcN-HCl on cell proliferation were also present, but not as
prominent. These ﬁndings of Terry et al. are similar to what
we have shown in Fig. 4.
The decrease in cell proliferation is also in accordance
with the recent results by Varghese et al., who found a de-
crease in cell proliferation with increasing GlcN-HCl con-
centration using a 3D cell culture system35. Using the
same system they found that GAG production was
1272 E. J. Uitterlinden et al.: Glucosamine effects on bovine cartilagemaximized at 2 mM and was inhibited at higher concentra-
tions. In contrast with these results, we found, using a differ-
ent 3D culture system, that total amount of GAG was
already signiﬁcantly lower compared to the control condition
when 0.5 mM GlcN-HCl was added and that this difference
only increased when GlcN-HCl concentration was 5 mM
(Fig. 3).
As in a lot of other in vitro studies, the major concern in
the interpretation of our data with respect to clinical applica-
bility is the concentration of GlcN used in our experimental
set-up. A recent study on oral bioavailability and plasma
pharmokinetics of GlcN in man with the standard 1500 mg
once-daily dosage, showed a peak plasma level of about
10 mM36. The GlcN concentrations we used in our experi-
ments were much higher. The reason we decided to use
GlcN concentrations up to 5 mM was mainly based on the
ﬁndings of Mroz and Silbert combined with the medium
Gluc concentration we used9,27. Mroz and Silbert sug-
gested that not only the absolute concentration of GlcN,
but the GlcN to Gluc ratio plays an important role in the uti-
lization and therefore efﬁcacy of exogenously provided
GlcN. In two studies using mouse chondrocytes or immor-
talized human chondrocytes in vitro, exogenous GlcN was
incorporated in newly formed CS when it was added at
equimolar concentrations with Gluc in the culture medium.
Chondrocytes preferably incorporated GlcN that was en-
dogenously formed from Gluc into CS when medium Gluc
concentration became higher than the exogenous GlcN
concentration. Since mean Gluc concentration in osteoar-
thritic knee-joint effusions was shown to be 5.4 mM, we
used medium with low Gluc concentration (5.55 mM) in or-
der to mimic the physiological situation37. Therefore, we de-
cided to add GlcN to the medium at concentrations
equimolar to, or lower than that of medium Gluc.
It still remains highly questionable which levels of GlcN
can be reached in articular cartilage and how high concen-
trations need to be to exert effects in vivo. In another study
on bioavailability, administration of GlcN-HCl at clinically
relevant levels to horses in a single dose led to a synovial
ﬂuid concentration of less than 10% of that measured in se-
rum at the same time38. However, after 6 h when GlcN was
almost completely cleared from serum, it could still be de-
tected in the synovial ﬂuid. Earlier studies with radio labeled
GlcN showed a special capacity of articular cartilage to ac-
cumulate and retain GlcN in animals and man39e42. Due to
this capacity, GlcN concentration surrounding the chondro-
cyte might be much higher than that measured in synovial
ﬂuid or serum. As we mentioned above, the importance of
the GlcN to Gluc ratio on the effectiveness of exogenous
GlcN was already stressed by other authors. With this ratio
in mind and the fact that Windhaber et al. measured a Gluc
concentration directly surrounding the chondrocytes of
1 mM, peri-cellular GlcN concentration probably does not
even have to reach 5 mM to be effective in vivo28.
The mechanism of action of GlcN might be explained by
interference of GlcN with Gluc utilization. GlcN-HCl and
GlcN-S seem to inhibit GAG synthesis, but adding increas-
ing concentrations of Gluc can reverse this effect (experi-
ment 4). In contrast, GlcN-Ac does not have such
inhibitory effects. A possible explanation for this might be
that Gluc and GlcN-HCl and GlcN-S can all be transported
into cells by members of the GLUT family, a Gluc trans-
porter system43. Therefore, GlcN can act as a competitive
inhibitor for Gluc uptake28. Also, intracellular competition
may occur at substrate level, since Gluc and GlcN are
both phosphorylated by the same enzyme: glucokinase44.
Phosphorylated GlcN in turn is an allosteric inhibitor ofglucokinase, which results in a negative feedback loop45.
Due to the direct competition between Gluc and GlcN-HCl
or GlcN-S at these different cellular levels, less Gluc-6-P
may become available to enter the glycolysis. It is com-
monly known that for optimal adenosine triphosphate
(ATP) production, a regular Gluc supply is needed since
chondrocytes are highly glycolytic cells46. So, by (partially)
blocking the glycolysis with exogenous GlcN-HCl or GlcN-
S, the intracellular ATP levels will eventually drop. This ef-
fect of exogenous GlcN on intracellular ATP levels has
been described earlier47,48. And in addition, other studies
have showed that depleting intracellular ATP, leads to a de-
crease of proteoglycan synthesis49,50. Thus with all these
earlier studies in mind, we hypothesize that GlcN-HCl or
GlcN-S addition might lead to intracellular ATP depletion,
which results in less energy for all intracellular processes
like, among others, ECM production and breakdown. The
explanation why GlcN-Ac does not show an inhibitory effect
on matrix synthesis may be that it is phosphorylated by a dif-
ferent enzyme and that no competition with Gluc occurs,
while its phosphorylated product can still be used for GAG
synthesis51.
Addition of more Gluc might reverse the competitive GlcN
effects, leading to a restored energy supply eventually nor-
malizingGAG synthesis, as could be observed in experiment
4. The latter is supported by data fromSandy et al.who found
that the degree of inhibition of aggrecanase response in rat
chondrocytes by GlcN was much reduced when medium
Gluc was increased from 5 mM to 15e25 mM18.
In summary, we conclude that addition of GlcN may inter-
fere with Gluc utilization and thereby compromising both an-
abolic and catabolic processes. In the current study, this
was demonstrated for anabolic processes by a decreased
ECM synthesis and for catabolic processes by a protection
against IL-1b mediated ECM breakdown. Based on these
results, we suggest that the claimed structure modifying ef-
fects of GlcN are more likely based on protection against
ECM degradation than production of new ECM.
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